PCSK9抑制剂相关不良事件的真实世界研究
该研究分析了医院登记库(n=164)及两个药物警戒数据库Lareb(n=149)和VigiLyze(n=15,554)中PCSK9抑制剂(阿利西尤单抗或依洛尤单抗)的不良事件。医院登记库中41.5%患者报告不良事件,最常见为注射部位反应(33.8%)和流感样疾病(27.9%),7%患者停药;Lareb和VigiLyze最常见为肌痛(12.8%和8.3%)。真实世界中PCSK9抑制剂耐受性良好,安全性特征与随机对照试验相当。
要点
- 真实世界中PCSK9抑制剂总体耐受性良好,安全性特征与RCT相当。
- 医院登记库最常见不良事件为注射部位反应和流感样疾病。
- 药物警戒数据库最常见不良事件为肌痛,未发现性别或药物间临床相关差异。
核心结论
- 真实世界中PCSK9抑制剂耐受性良好,总体安全性特征与随机对照试验相当。
研究设计与样本
- 分析医院登记库(n=164)及两个药物警戒数据库Lareb(n=149)和VigiLyze(n=15,554)中PCSK9抑制剂相关不良事件报告。
主要发现
- 医院登记库中41.5%患者报告任何不良事件,最常见为注射部位反应(33.8%)和流感样疾病(27.9%)。
- 医院登记库中12例患者(7%)停用PCSK9抑制剂。
- Lareb和VigiLyze数据库最常见不良事件为肌痛(分别为12.8%和8.3%)。
- 未观察到性别或药物之间临床相关差异,未识别出特定不良事件风险亚组。
- 随访期间大多数患者(71.1%)不良事件缓解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In randomized clinical trials (RCTs) proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors showed a favorable safety profile, however, "real-world" data on adverse events (AEs) is scarce. Three datasets, a hospital registry (n = 164), and two Pharmacovigilance databases, Lareb (n = 149) and VigiLyze (n = 15,554), reporting AEs attributed to PCSK9 inhibitors (alirocumab or evolocumab) prescribed in clinical practice were analyzed. In the hospital registry, 41.5% of the patients reported any AE, most often injection-site reactions (33.8%) and influenza-like illness (27.9%). Twelve patients (7%) discontinued PCSK9 inhibitor treatment. Most common AE reported in the Lareb and VigiLyze database was myalgia (12.8% and 8.3%, respectively). No clinically relevant differences in gender or between drugs were observed. No specific subgroup of patients could be identified at risk of developing AEs. During follow-up, AEs resolved in most patients (71.1%). In a real-world setting, PCSK9 inhibitors are well tolerated with an overall safety profile comparable to RCTs.
引用
- Gürgöze MT, Muller-Hansma AHG, Schreuder MM, et al. Adverse Events Associated With PCSK9 Inhibitors: A Real-World Experience. Clin Pharmacol Ther. 2018. PMID: 30053327. doi:10.1002/cpt.1193
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。